EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Immunopeptidomics identified antigens for mRNA-lipid nanoparticle vaccines with alpha-galactosylceramide in multiple myeloma therapy

Arne Van der Vreken, Fabien Thery, Chenggong Tu, Kevin Mwangi, Sofie Meulewaeter, Lien De Beck, Edith Janssens, Kim De Veirman, Karin Vanderkerken, Elke De Bruyne, Lorenzo Franceschini, Francis Impens und 4 weitere

Journal for ImmunoTherapy of Cancer · 2025

DOI: 10.1136/jitc-2024-010673 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2025. Verfasst von Arne Van der Vreken und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences Brussels, Translational Oncology Research Center, Vrije Universiteit Brussel, Brussels, Belgium karine.breckpot@vub…. Hauptthemen laut MEDLINE: Multiple Myeloma, Galactosylceramides, Nanoparticles, Cancer Vaccines. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Willy Gepts, King Baudouin Foundation, Catharina Weekers.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Invariant natural killer T (iNKT) cells and CD8 + T cells are key in the immune response against multiple myeloma (MM), a largely incurable blood cancer. Immunization is a promising strategy to activate these T cell populations. To our knowledge, immunization with messenger RNA (mRNA) and the iNKT agonist, α-galactosylceramide (αGC), has not been studied in MM, as knowledge on clinically relevant antigens in preclinical MM models is lacking.

Methods

Microarray data and immunopeptidomics (imPep) were used to identify candidate antigens for immunization in 5TMM models. Galsomes, lipid nanoparticles containing antigen mRNA and αGC were used to immunize 5T33MM-bearing mice. This treatment was combined with a CD40 agonist. Tumor burden and activation of iNKT cells and CD8 + T cells were studied using M-protein electrophoresis, flow cytometry and ELISA.

Results

RNA transcripts revealed survivin as a candidate antigen. Prime-boost Galsomes therapy targeting survivin significantly reduced M-protein levels despite low survivin-specific T cell responses. Further analysis showed potential T cell fratricide. ImPep revealed HSP60, Idiotype, PICALM and EF1A1 as candidate antigens. Prime-boost therapy with Galsomes targeting these antigens reduced MM growth significantly when combined with a CD40 agonist, coinciding with significantly improved antigen presentation, costimulation and cytotoxicity of iNKT cells and CD8 + T cells.

Conclusion

These findings highlight the potential of Galsomes, an mRNA vaccine designed to activate CD8 + T cells and iNKT cells, for MM therapy, and emphasize the importance of combinatorial approaches, addressing immune anergy for effective MM immunotherapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaGalactosylceramidesNanoparticlesCancer VaccinesRNA, MessengerAntigens, NeoplasmAnimalsMiceHumansNatural Killer T-CellsCD8-Positive T-LymphocytesCell Line, TumorFemaleNanovaccinesLiposomes

Stichwörter der Autor:innen

ImmunotherapyMajor histocompatibility complex - MHCMultiple MyelomaNanoparticleVaccine

Substanzen

Galactosylceramidesalpha-galactosylceramideCancer VaccinesRNA, MessengerLipid NanoparticlesAntigens, NeoplasmNanovaccinesLiposomes

Autor:innen und Institutionen

  • Department of Biomedical Sciences Brussels, Translational Oncology Research Center, Vrije Universiteit Brussel, Brussels, Belgium karine.breckpot@vub.be Eline.Menu@vub.be arne.van.der.vreken@vub.be.
  • VIB-UGent Center for Medical Biotechnology, VIB, Ghent, Belgium.
  • Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.
  • Department of Biomedical Sciences Brussels, Translational Oncology Research Center, Vrije Universiteit Brussel, Brussels, Belgium.
  • Department of Pharmaceutics, Laboratory of Physical Pharmacy and General Biochemistry, Ghent Research Group on Nanomedicines, Universiteit Gent, Ghent, Belgium.
  • Cancer Research Institute Ghent (CRIG), Universiteit Gent, Ghent, Belgium.

Förderung

  • Willy Gepts
  • King Baudouin Foundation
  • Catharina Weekers
  • Vrije Universiteit Brussel
  • Kom op tegen Kanker
  • Fonds Wetenschappelijk Onderzoek
  • Ghent University

Zitieren

APA

Van der Vreken, A., Thery, F., Tu, C., Mwangi, K., Meulewaeter, S., De Beck, L., Janssens, E., De Veirman, K., Vanderkerken, K., De Bruyne, E., Franceschini, L., Impens, F., Verbeke, R., Lentacker, I., Menu, E., & Breckpot, K. (2025). Immunopeptidomics identified antigens for mRNA-lipid nanoparticle vaccines with alpha-galactosylceramide in multiple myeloma therapy. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2024-010673

Vancouver

Van der Vreken A, Thery F, Tu C, Mwangi K, Meulewaeter S, De Beck L, et al. Immunopeptidomics identified antigens for mRNA-lipid nanoparticle vaccines with alpha-galactosylceramide in multiple myeloma therapy. Journal for ImmunoTherapy of Cancer. 2025. doi:10.1136/jitc-2024-010673

BibTeX
@article{VanderVreken2025,
  author = {Van der Vreken, Arne and Thery, Fabien and Tu, Chenggong and Mwangi, Kevin and Meulewaeter, Sofie and De Beck, Lien and Janssens, Edith and De Veirman, Kim and Vanderkerken, Karin and De Bruyne, Elke and Franceschini, Lorenzo and Impens, Francis and Verbeke, Rein and Lentacker, Ine and Menu, Eline and Breckpot, Karine},
  title = {Immunopeptidomics identified antigens for mRNA-lipid nanoparticle vaccines with alpha-galactosylceramide in multiple myeloma therapy},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  doi = {10.1136/jitc-2024-010673}
}
Kostenlos starten →